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Abstract
Background: Among the most vulnerable people in society are children and this is especially so in their access to
health care Off-label prescription of paediatric medicines is known to be associated with safety outcomes some of
which may be serious. This study identifies frequently prescribed children’s medicines that are not readily available
in Ghana and are prepared extemporaneously.
Method: All prescriptions for extemporaneous oral preparations for children presented to the local production unit
of the Korle-Bu Teaching Hospital from November, 2013 were eligible for the study. Information from such
prescriptions was recorded in a systematic format. Presence of the prescribed medicine on the World Health
Organization Children’s Medicine List was ascertained in addition to the anatomical and therapeutic classification
code. The registration of the prescribed medicine for paediatric use by the Food and Drugs Authority, Ghana was
also checked. Descriptive statistics of the data was presented.
Results: In all 622 prescriptions for 35 different paediatric formulations were served. Prescriptions from several
health facilities including government hospitals (6.6 %, N = 622), private hospitals (2.4 %, N = 622) and the University
of Ghana hospital (1.1 %, N = 622) were all honoured. Some of the prescribed medicines (Baclofen, Clonazepam,
Hydroxyurea and Lamotrigine) were neither on the World Health Organization Children’s Medicine list nor
registered with the Food and Drugs Authority, Ghana. Most prescribed medicines (88.6 %, N = 35) were for
non-communicable diseases.
Conclusion: Paediatric prescriptions including off-label medicines are prescribed and formulated extemporaneously
in this setting. Steps should be taken to improve access and monitor benefit-risk profiles of paediatric medicines in
order to improve treatment outcomes among children.
Keywords: Extemporaneous formulation, Paediatric medicines, Off-label use, Ghana
Background
Children are among the most vulnerable people in
society, and concerted efforts are being made to increase
their access to health care [1]. In times of illness, children
need the appropriate medicines at the right time. Such
medicines should be safe, efficacious, affordable and cost-
effective.
Most adult oral medicines exist as tablets, capsules
or caplets while most paediatric formulations are
available as solutions, syrups, suspensions or granules
for suspension. Adult medicines that may be used by
children are not always readily available as paediatric
formulations. For such medicines the best option is
an extemporaneous formulation. It is on record that
off-label use of medicines in children is associated
with adverse reactions [2].
Extemporaneous preparations are available only in
limited hospital pharmacies in Ghana, although most
hospital pharmacies are superintended by pharmacists
capable of producing such formulations. No private
independent facilities produce individualised extempo-
raneous preparations in the country to date. The resul-
tant pressure on the few existing facilities producing
such formulations is extreme. In the end, it is parents or
guardians of affected children who endure the most of
such inadequacies by searching for these limited
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pharmacies because there are no arrangements for medi-
cine pick-ups. This may lead to late treatment initiation
among new patients and non-persistence among those
already on treatment.
In Ghana, there are no guidelines for paediatric ex-
temporaneous preparations, in contrast to places like
Australia [3], for instance. There is no particular mecha-
nism on how the price of such products should be calcu-
lated. To make matters worse, such products are not
represented on the national health insurance medicines
list, and patients must pay for these medicines out-of-
pocket.
Ghana has an essential medicines list, which was
adapted for use from the WHO Essential Medicines
list [4]. The Ministry of Health Ghana under the Ghana
National Drugs Programme (GNDP) has accepted the
WHO priority medicines list for children and mater-
nal health as a working document [5]. Having these
medicine lists is necessary but not sufficient to guarantee
treatment. Policy makers must ensure that systems
are in place to provide the required medicines in the
medicines list. Although extemporaneous formularies
are difficult to obtain, Pharminfotech (New Zealand)
has a formulary that is electronically accessible and
free of charge [6].
This study aimed to identify frequently prescribed
children’s medicines that are not readily available as




The study was carried out at the local production
unit (LPU) of the Korle-Bu Teaching Hospital
(KBTH) in Accra, Ghana. KBTH is a referral hospital
with a 2000-bed capacity. The LPU is the arm of the
Pharmacy Department of the hospital responsible for
various extemporaneous formulations. Approximately
50 patients receive extemporaneous preparations from
the LPU every week. These are predominantly in the
form of oral suspensions and syrups. Preparations are
formulated here with guidance from the Pharmin-
fotech [6] online formulary.
Most of the prescriptions were from the hospital’s Child
Health Sub-Budget Management Centre (sub-BMC) and
the children’s unit of the National Cardio-Thoracic Centre
(NCTC). The rest of the prescriptions were from other
hospitals in the country.
Participants and data collection
All prescriptions for extemporaneous oral preparations
for children presented to the LPU from November
2013 were eligible for the study. Information from such
prescriptions was recorded in a systematic format. The
date, treatment centre, patient’s name and sex, age, name
of preparation, and parent/caregiver-reported morbidity
were captured prospectively. The data were anonymized
for this study. Parent/caregiver reported morbidity was
recorded because we did not use patient’s health records.
Data capture continued until no new prescriptions were
received for 14 continuous days. Patients who came for
the same medication with different prescriptions on diffe-
rent occasions were captured more than once. However,
those who came for refills on the same prescription form
were only captured once.
Ethics statement
This operational research was approved by the Korle-
Bu Teaching Hospital’s Management as part of the
Programme of Work of the Pharmacy Department to
determine prescriptions patterns of paediatric medicines
and to improve forecasting for planning purposes. The
activity is conducted periodically to update the hospital
formulary. The study is about prescribing practices in the
hospital and poses less than minimum risk to patients.
Because of these, there was no need for ethical approval
after management’s approval.
Analysis
The presence of the prescribed medicine on the WHO
Children’s Medicines List was ascertained. Registration
of the prescribed medicine for paediatric use by the
Food and Drugs Authority (FDA) Ghana was also deter-
mined. The anatomical and therapeutic chemical (ATC)
classification by the WHO [7] was also identified.
Descriptive statistics of the data are presented using
Stata intercooled version 12 (Stata Corp LP, College
Station, TX, USA).
Results
There were 622 individual prescriptions for extempo-
raneous preparations that were submitted during the
study period. The highest proportion of prescriptions
(0.35, 217/622) was in the first month of the study.
This amount decreased gradually with time. Prescrip-
tions from the Child Health sub-BMC and the NCTC
amounted to 87.1 % of all requests for paediatric for-
mulations, as would be expected given their asso-
ciation with the LPU. One prescription from Tamale
Teaching Hospital, the most distant treatment site from
the LPU (a distance of about 616 km from the study
site) was dispensed. There were 7 (1.1 %) prescrip-
tions from the University of Ghana hospital (Table 1).
Prescriptions dispensed involved those for neonates,
infants and children below 9 years.
The most frequently reported morbidities were car-
diovascular diseases, anaemia and seizures. Table 2
shows the list of drugs and their ATC classifications.
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Furosemide (31.2 %, N = 622), spironolactone (28.1 %,
N = 622), folic acid (9.0 %, N = 622), propranolol
(8.0 %, N = 622) and clonazepam (3.2 %, N = 622)
suspensions were the top five most dispensed medicines.
Some medicines were also dispensed, which were neither
registered by the FDA Ghana nor present on the WHO
Children Medicines List 2010 [1]. These included baclofen
(1.9 %, N = 622), clonazepam (3.2 %, N = 622), hydro-
xyurea (2.6 %, N = 622) and lamotrigine (1.0 %, N = 622).
Discussion
This study shows that a number of prescribed medi-
cines for paediatric use are not readily available on
the Ghanaian market, and are formulated extempo-
raneously using adult tablets. The formulations are
prepared only at restricted facilities and care givers
have to travel long distances for their medicines.
Furthermore, the study reveals that some of the pre-
scribed medicines are neither present on the WHO
priority medicines list for children [1] nor registered
with the Food and Drugs Authority in the country.
The study also reveals that most of the formulated
medicines are for management of non-communicable
disease.
This article emphasizes the need to provide alter-
native and appropriate formulations for infants and
children where manufactured formulations are not
readily available. Our findings also suggest that phar-
macists should learn the techniques involved in pre-
paration of extemporaneous products to make life
easier for patients and their caregivers without com-
promising safety.
There is an urgent need for immediate assessment
and harmonization of the paediatric extemporaneous
preparation situation in Ghana. Pharmacists should be
trained in all regional hospitals and encouraged to
train pharmacists in other practice settings through-
out their regions. There should be proper evaluation
of prescription patterns and provision of basic accou-
trements for effective production and dispensing.
Pharmacists involved with such formulations should
be well motivated to deliver medication promptly and
avoid excessive patient waiting times.
About 90 % of formulated medicines are indicated in
management of non-communicable diseases. According
to the WHO, congenital anomalies and other non-
communicable diseases contribute to 7 % of all deaths
among infants and children aged below 5 years [8].
This underscores the importance of these formula-
tions or a search for appropriate pre-formulated alter-
natives. Policy makers need to make an immediate
intervention to bring this situation under control.
Reports from UNICEF indicate that in 2012 about
44 % of all deaths in children younger than 5 years
occurred in neonates, but most of these deaths were
preventable [9]. Although malnutrition has been cited
as one of the underlying reasons for these deaths,
unavailability of the appropriate prescribed medicine
could also be a contributing factor [9].
The fact that teaching hospitals, university hospitals,
government hospitals, private hospitals, and clinics are
all prescribing these paediatric formulations indicates
the extent to which they have become essential. The
high number of prescriptions at the KBTH Child Health
sub-BMC and the NCTC (both referral centres) in our
study clearly shows that these medicines are mostly pre-
scribed by specialists and/or consultants. This calls for
re-evaluation of the national essential medicines list.
The use of unlicensed or off-label medicines among
paediatric patients has been reported to be signifi-
cantly associated with an increased risk of developing
an adverse drug reaction [2]. Furthermore, among
some hospitalised children, up to 90 % of medicines
are prescribed off-label [10–14]. For those medicines









November 2013 217 35.0 Not applicable
(N/A)
December 2013 182 29.2 N/A
January 2014 106 17.0 N/A
February 2014 117 18.8 N/A
Sex
Male 272 43.7 N/A
Female 350 56.3 N/A
Hospitals
Child Health Department 293 47.1 0
NCTCa 249 40.0 0
Government Hospitals 41 6.6 72
37 Military Hospital 16 2.6 12
Private Hospitals/Clinics 15 2.4 15





≤ 1 month 37 6.0 N/A
> 1 month–12 months 167 26.8 N/A
> 12 months – 60 months 250 40.2 N/A
> 60 months 25 4.0 N/A
Missing 143 23.0 N/A
aNational Cardio-Thoracic Centre. bAverage distance was used because of
grouped data
Ankrah et al. BMC Health Services Research  (2016) 16:198 Page 3 of 5
that are neither present on the Children’s Medicines
list nor registered with the FDA Ghana for paediatric
use, measures should be taken to rectify the situation
and encourage proper monitoring of benefit-risk pro-
files of such medicines among this subgroup.
The use of specially formulated medicines is not
limited to low and medium income countries like Ghana.
In the United Kingdom (UK) these products are popularly
called “specials” or “special order product” [15]. Most
specials are unlicensed formulations of a licensed medi-
cine [15]. The difference is that such facilities are well
established, accessible, and regulated. Special formulations
are available in New Zealand [6] and Australia [3] where
well established formularies are used.
Our study captured only those prescriptions that were
filled. If prescriptions that were not dispensed had also
been captured, this would have been more interesting.
This would further emphasize the magnitude of the
unmet need for paediatric formulations in Ghana. There
were missing values for patient’s age. This occurred
because data were captured from prescription forms,
some of which did not indicate the patient’s age. This
information would have allowed the most at-risk age
group for these formulations to be identified.
Conclusion
In conclusion, the non-availability of pre-formulated
paediatric medicines in Ghana has resulted in the
extemporaneous formulation of such medicines using
adult tablets. Only limited facilities provide this service.
Ghana, and other countries facing this challenge could
learn from the UK by encouraging the establishment of
facilities for the preparation of specials at strategic
positions throughout the country and regulate them.
The current situation poses a challenge to care givers
who have to travel long distance to procure these
Table 2 Prescribed medicines at baseline with ATC codes





for oral paediatric use
Availability on children EMLa ATC code [7]
Baclofen 12 (1.9) No -b No M03BX01
Captopril 15 (2.4) Yes No No C09AA01
Clonazepam 20 (3.2) No - No N03AE01
Digoxin 2 (0.3) Yes No Yes C01AA05
Domperidone 2 (0.3) Yes Yes No A03FA03
Enalapril 2 (0.3) Yes No Yes C09AA02
Folic acid 56 (9.0) Yes Yes Yes B03BB01
Furosemide 194 (31.2) Yes No Yes C03CA01
Hydroxyurea 16 (2.6) No - No L01XX05
Levetiracetam 2 (0.3) Yes No No N03AX14
Lamotrigine 6 (1.0) No - No N03AX09
Lisinopril 3 (0.5) Yes No No C09AA04
Metoclopramide 2 (0.3) Yes Yes Yes A03FA01
Nalidixic Acid 2 (0.3) Yes No No J01MB02
Nifedipine 4 (0.6) Yes No No C08GA02
Nitrofurantoin 3 (0.5) Yes Yes J01XE01
Phenobarbitone 14 (2.3) Yes Yes Yes N03AA02
Prednisolone 2 (0.3) Yes Yes Yes H02AB06
Propranolol 50 (8.0) Yes Yes Yes C07BA05
Pyrimethamine 3 (0.5) No - Yes P01BD01
Ranitidine 2 (0.3) Yes Yes A02BA02
Risperidone 7 (1.1) Yes No No N05AX10
Sildenafil citrate 13 (2.1) Yes No No G04BE03
Spironolactone 175 (28.1) Yes No Yes C03DA01
Sulfadiazine 3 (0.5) No - Yes J01EC02
Topiramate 3 (0.5) Yes - No N03AX12
Others 9 (1.4) - - - -
aWHO Model Formulary for Children 2010. bThere was no information on product
Ankrah et al. BMC Health Services Research  (2016) 16:198 Page 4 of 5
medicines. Some of these medicines are neither present
on the WHO Children’s Medicines list nor registered
with the FDA Ghana, emphasizing the possibility of off-
label use of medicines. Steps should be taken by policy
makers to involve more facilities in the preparation of
these medicines while the search for pre-formulated
forms continue.
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